产品名称

Solcitinib - GSK 2586184 | GLPG 0778

产品货号

Axon 2539 CAS [1206163-45-2] MF C22H23N5O2MW 389.45 Purity: 98% Soluble in DMSO Description Selective JAK1 inhibitor originally developed for the treatment of systemic lupus erythematosus, psoriasis and ulcerative colitis. KEYWORDS: Solcitinib | supplier | JAK1 inhibitor | GSK 2586184 | GLPG 0778 | GSK2586184 | GLPG0778 | CAS [1206163-45-2] | JAK-STAT Pathway | JAK | Inhibitor | Janus kinase | inflammatory | lupus erythematosus | psoriasis | ulcerative colitis

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Solcitinib - GSK 2586184 | GLPG 0778

Based on 13 reference(s) in Google Scholar 9 10 13

Axon 2539

CAS [1206163-45-2]

MF C22H23N5O2
MW 389.45

Purity: 98%
Soluble in DMSO

Solcitinib

Description

Selective JAK1 inhibitor originally developed for the treatment of systemic lupus erythematosus, psoriasis and ulcerative colitis.

KEYWORDS: Solcitinib | supplier | JAK1 inhibitor | GSK 2586184 | GLPG 0778 | GSK2586184 | GLPG0778 | CAS [1206163-45-2] | JAK-STAT Pathway | JAK | Inhibitor | Janus kinase | inflammatory | lupus erythematosus | psoriasis | ulcerative colitis

C.J.M. Menet et al. Novel triazolopyridine compounds as JAK kinase inhibitors useful for the treatment of degenerative and inflammatory diseases and their preparation. PCT Int. Appl. (2010), WO 2010010190 A1.

Cell Signaling & Oncology Epigenetics Immunology Pain & Inflammation JAK-STAT EC 2.7.10.2 JAK

Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases

Chemical name

N-(5-(4-(3,3-dimethylazetidine-1-carbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide

Parent CAS No.

[1206163-45-2]

产品资料